Haematopoietic stem cell transplantation for autoimmune diseases

被引：0
作者：
Joost F. Swart
Eveline M. Delemarre
Femke van Wijk
Jaap-Jan Boelens
Jürgen Kuball
Jacob M. van Laar
Nico M. Wulffraat
机构：
[1] Paediatric Immunology,Department of Haematology
[2] Wilhelmina Children's Hospital,Department of Rheumatology and Immunology
[3] University Medical Centre Utrecht,undefined
[4] Laboratory of Translational Immunology,undefined
[5] University Medical Centre Utrecht,undefined
[6] University Medical Centre Utrecht,undefined
[7] University Medical Centre Utrecht,undefined
来源：
Nature Reviews Rheumatology | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Haematopoietic stem cell transplantation (HSCT) requires a careful selection of patients according to autoimmune disease, and a consideration of therapeutic alternatives, risks and benefits, and the expertise of the transplantation teamThe need for graft manipulation before HSCT is uncertainIndividualized conditioning regimens might provide increased long-term remission rates, and stem cell rescue could minimize the duration of neutropenia and improve the containment of virusesHSCT resets the immune system by renewing the CD4+ T cell compartment, especially within the Treg cell population, and by restoring T cell receptor diversity and functionIn patients with systemic sclerosis, HSCT results in increased mortality within the first year but a considerable long-term, event-free survival benefit afterwards
引用
收藏
页码：244 / 256
页数：12
相关论文
共 157 条
[11]  
Baldwin JL(1994)Immune ablation followed by allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases? Stem Cells 12 125-780
[12]  
Storb R(1996)Autologous haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease Ann. Rheum. Dis. 55 779-645
[13]  
Thomas ED(1997)Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant. 19 643-790
[14]  
Mannik M(2012)Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant. 47 770-23
[15]  
Jacobs P(2016)Consensusdocument: Autologe hematopoïetische stamceltransplantatie bij ernstige diffuse cutane systemische sclerose NT Reum. 19 17-82
[16]  
Vincent M(2016)Low-dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease Eur. J. Haematol. 97 78-6
[17]  
Martell R(2015)PBSC mobilization in patients with autoimmune diseases: what's next Eur. J. Haematol. 97 5-4773
[18]  
Roubenoff R(2009)Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for J. Clin. Oncol. 27 4767-2357
[19]  
Jones RJ(2015)Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a phase II clinical trial Transfusion 55 2351-635
[20]  
Karp JE(2011)Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens Bone Marrow Transplant. 46 627-273
12345678910